Company intelligence / Profile preview

Singapore Institute of Advanced Medicine

Singapore, Singaporeadvancedmedicine.sg ↗

Ownership: Private
Employees: ~79
Development stage: Other

Overview

Singapore Institute of Advanced Medicine delivers advanced cancer therapies including proton and x-ray therapy, radiation oncology, and precision imaging. Collaborations include a Phase 1/2 multinational trial with EnGeneIC (EDV nanocell for EGFR-positive advanced solid tumors), and historically rapid rollout post-COVID with expanded therapy and diagnostics at Biopolis.

Therapeutic areas: CardiovascularOncologyNeurology
Modalities: Proton therapyRadiation therapyTheranosticMedical imagingSmall molecule
Industry: Academic Hospital/University/Research

Partnerships

EnGeneICPhilipsVarianSiemens

Beyond the preview

Go deeper on Singapore Institute of Advanced Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Singapore Institute of Advanced Medicine.